United States - English - NLM (National Library of Medicine)

novel laboratories, inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - amlodipine 5 mg - amlodipine and valsartan tablets  are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine and the arb class to which valsartan principally belongs. there are no controlled trials demonstrating risk reduction with amlodipine and valsartan tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703) - amlodipine 5 mg - amlodipine and benazepril hydrochloride capsules, usp are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent. - do not coadminister aliskiren with angiotensin receptor blockers (arbs), ace inhibitors, including amlodipine and benazepril hydrochloride in patients with diabetes. - amlodipine and benazepril hydrochloride is contraindicated in patients with a history of angioedema, with or without previous ace inhibitor treatment, or patients who are hypersensitive to benazepril, to any other ace inhibitor, to amlodipine, or to any of the excipients of amlodipine and benazepril hydrochloride capsules. - amlodipine and benazepril hydrochloride is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer amlodipine and benazepril hydrochloride capsules within 36 hours of switching to or from a neprilysin inhibitor, e.g., sacubitril/valsartan

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg); valsartan, quantity: 80 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; crospovidone; colloidal anhydrous silica; titanium dioxide; hypromellose; purified talc; macrogol 4000; iron oxide yellow - amlodipine/valsartan novartis is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 6.94 mg; telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate; croscarmellose sodium; brilliant blue fcf aluminium lake; mannitol; magnesium stearate; microcrystalline cellulose; povidone; silicon dioxide; iron oxide yellow; sodium hydroxide; meglumine; iron oxide black; isomalt - treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.87 mg; telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: mannitol; iron oxide black; brilliant blue fcf aluminium lake; calcium hydrogen phosphate; sodium hydroxide; iron oxide yellow; meglumine; isomalt; croscarmellose sodium; magnesium stearate; povidone; microcrystalline cellulose; silicon dioxide - treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 6.94 mg; telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: mannitol; povidone; iron oxide black; silicon dioxide; croscarmellose sodium; calcium hydrogen phosphate; meglumine; isomalt; sodium hydroxide; brilliant blue fcf aluminium lake; iron oxide yellow; microcrystalline cellulose; magnesium stearate - treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.87 mg; telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: iron oxide black; iron oxide yellow; brilliant blue fcf aluminium lake; microcrystalline cellulose; croscarmellose sodium; calcium hydrogen phosphate; silicon dioxide; meglumine; povidone; mannitol; sodium hydroxide; isomalt; magnesium stearate - treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.87 mg; telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: sodium hydroxide; meglumine; povidone; magnesium stearate; citric acid; mannitol; colour - treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 6.935 mg; telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: sodium hydroxide; meglumine; povidone; magnesium stearate; citric acid; mannitol; colour - treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.87 mg; telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: sodium hydroxide; meglumine; povidone; magnesium stearate; citric acid; mannitol; colour - treatment of hypertension. treatment should not be initiated with this fixed-dose combination.